CAR-T therapy clinical trials, in English

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy.

NCT05621291 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.

NCT05672147 · Official ClinicalTrials.gov record · City of Hope Medical Center

This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Castration-resistant prostate cancer continues to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production.

NCT05805371 · Official ClinicalTrials.gov record · City of Hope Medical Center

This is a single-arm, open-label study to measure the how well it works and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia

NCT05979363 · Official ClinicalTrials.gov record · Institute of Hematology & Blood Diseases Hospital, China

This study wants to test the whether it is safe and how hard side effects are to live with of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer. The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Administration.

NCT06096038 · Official ClinicalTrials.gov record · UNC Lineberger Comprehensive Cancer Center

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

NCT06579469 · Official ClinicalTrials.gov record · St. Jude Children's Research Hospital

This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \[IT\]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures.

NCT06895473 · Official ClinicalTrials.gov record · OHSU Knight Cancer Institute

A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to measure the how well it works and safety of HBI0101 CART.

NCT06971380 · Official ClinicalTrials.gov record · Polina Stepensky

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy where the immune system cell, T-cell, is changed to attack cancer cells.

NCT07003295 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary how well it works of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to measure the whether it is safe and how hard side effects are to live with of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R).

NCT07085104 · Official ClinicalTrials.gov record · Allogene Therapeutics

A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies

NCT07108868 · Official ClinicalTrials.gov record · University Hospital Tuebingen

This is a phase I, treatment, single-arm, open-label, dose-finding treatment study designed to measure the safety and preliminary how well it works of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.

NCT07221032 · Official ClinicalTrials.gov record · Medical College of Wisconsin

The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective.

NCT07223021 · Official ClinicalTrials.gov record · Memorial Sloan Kettering Cancer Center

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial how well it works in the treatment of relapsed or refractory malignant hematological tumors.

NCT07239323 · Official ClinicalTrials.gov record · Chongqing Precision Biotech Co., Ltd

This is a Phase 1b open-label, multicenter, non-randomly assigned study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.

NCT07250269 · Official ClinicalTrials.gov record · Gracell Biotechnologies (Shanghai) Co., Ltd.

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to measure the whether it is safe and how hard side effects are to live with in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

NCT07295847 · Official ClinicalTrials.gov record · AstraZeneca

This study is an open-label, single-arm early exploratory clinical study, aiming to measure the safety, tolerability and preliminary how well it works of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

NCT07322159 · Official ClinicalTrials.gov record · Institute of Hematology & Blood Diseases Hospital, China

This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients with high-grade gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). EGFR/IL13Rα2 pool-CAR T cells are a type of CAR T cell therapy.

NCT07544992 · Official ClinicalTrials.gov record · City of Hope Medical Center

Background: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to treat.

NCT07572136 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This is an open -label phase I /IIa study designed to measure the safety and how well it works of IMC001 in patients with advanced epithelial solid tumors. The study comprises two parts: a phase I dose-escalation phase and a phase IIa phase to further explore and validate how well it works .In the Phase I dose-escalation phase of this study, approximately 7-15 subjects with advanced epithelial solid tumors will be recruited to measure the whether it is safe and how hard side effects are to live with of autologous IMC001 treatment .

NCT07644403 · Official ClinicalTrials.gov record · Suzhou Immunofoco Biotechnology Co., Ltd

This study is a Phase 1/2 dose-finding and dose-confirmation study to measure the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).

NCT07735533 · Official ClinicalTrials.gov record · Umoja Biopharma

This study wants to assess the how well it works and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.

NCT07825064 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The study is a biological, drug-related, non-treatment watch-and-measure (no experimental treatment required) study with both retrospective and prospective components. No experimental diagnostic procedures, investigational medicinal products, or medical devices will be used, and samples will be collected as part of routine clinical practice.

NCT07915102 · Official ClinicalTrials.gov record · Ciceri Fabio

This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to measure the safety, tolerability, preliminary how well it works, and cellular kinetics of an in vivo CAR-T cell immunotherapy targeting CD19 sequentially followed by CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The investigational product is a targeted lentiviral vector that transduces the patient's endogenous T/NK cells in situ; no leukapheresis, ex vivo manufacturing, or lymphodepleting conditioning is required.

NCT07927816 · Official ClinicalTrials.gov record · Liping Dou